| Autor: |
Zhou J; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Yiying Quah J; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Ng Y; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Chooi JY; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore., Hui-Min Toh S; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Lin B; Department of Hematology-Oncology, National University Cancer Institute, Republic of Singapore., Zea Tan T; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Hosoi H; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore., Osato M; Cancer Science Institute of Singapore, Department of Pediatrics, National University of Singapore., Seet Q; ASLAN Pharmaceuticals, Republic of Singapore., Ooi LAG; ASLAN Pharmaceuticals, Republic of Singapore., Lindmark B; ASLAN Pharmaceuticals, Republic of Singapore., McHale M; ASLAN Pharmaceuticals, Republic of Singapore., Chng WJ; Cancer Science Institute of Singapore, National University of Singapore, Republic of Singapore. |
| Abstrakt: |
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid leukemia except for mutant isocitrate dehydrogenase 1/2. Dihydroorotate dehydrogenase catalyses the fourth step of the de novo pyrimidine synthesis pathway. ASLAN003 is a highly potent dihydroorotate dehydrogenase inhibitor that induces differentiation, as well as reduces cell proliferation and viability, of acute myeloid leukemia cell lines and primary acute myeloid leukemia blasts including in chemo-resistant cells. Apoptotic pathways are triggered by ASLAN003, and it also significantly inhibits protein synthesis and activates AP-1 transcription, contributing to its differentiation promoting capacity. Finally, ASLAN003 substantially reduces leukemic burden and prolongs survival in acute myeloid leukemia xenograft mice and acute myeloid leukemia patient-derived xenograft models. Notably, the drug has no evident effect on normal hematopoietic cells and exhibits excellent safety profiles in mice, even after a prolonged period of administration. Our results, therefore, suggest that ASLAN003 is an agent targeting dihydroorotate dehydrogenase with potential in the treatment of acute myeloid leukemia. ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients. |
